智通财经网·2026-04-01 08:45Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the transfer of the marketing authorization of artificial bile acid metronidazole capsules, indicating compliance with post-marketing change management requirements [1] Group 1: Company Developments - The company submitted a supplementary application for the change of marketing authorization holder in March 2026, which has now been approved [1] - The approval allows the company to transfer the marketing authorization for the product, which is indicated for acute pericoronitis, local alveolar abscess, pulpitis, and apical periodontitis [1] Group 2: Market Insights - The sales revenue of artificial bile acid metronidazole capsules in Chinese public medical institutions is projected to be approximately RMB 579 million in 2024 [1]